Mirikizumab

Highest phase reached
Approved
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk
First approval year
2023
www.ebi.ac.uk

First approval year
2023
www.ebi.ac.uk
Listing at source
Listed
Highest phase reached
Approved
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Mirikizumab
www.ebi.ac.uk

  • omvoh
  • Omvoh

  • ly 3074828
  • LY-3074828
  • ly3074828
  • LY3074828
  • mirikizumab
  • Mirikizumab
  • Mirikizumab - IV
  • Mirikizumab (MIR)
  • mirikizumab [INN]
  • MIRIKIZUMAB [JAN]
  • Mirikizumab [MI]
  • MIRIKIZUMAB [USAN]
  • Mirikizumab [WHO-DD]
  • mirikizumab inn
  • Mirikizumab IV
  • mirikizumab jan
  • mirikizumab mi
  • mirikizumab mrkz
  • Mirikizumab mrkz [WHO-DD]
  • mirikizumab mrkz who dd
  • mirikizumab usan
  • mirikizumab who dd
  • Mirikizumab- IV
  • Mirikizumab-mrkz

CAS registry numbers
  • 1884201-71-1
ChEMBL ID
CHEMBL3990014
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • Z7HVY03PHP

  • L04AC
  • L04AC24
Sources for recorded values
www.ebi.ac.uk

  • 2668384
  • 2668385

Applicant
ELI LILLY AND CO
Approval date
26 Oct 2023
Application number
BLA761279

Status
Authorised
Status date
26 May 2023
Authorisation date
26 May 2023
Approved indications
Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
Product number
EMEA/H/C/005122
Authorisation holder
Eli Lilly Nederland B.V.
Priority medicines scheme
No
Generic
No
Biosimilar
No
Generic medicines
0
Biosimilar medicines
0
Advanced therapy
No
Conditional approval
No
Additional monitoring
Yes
Accelerated assessment
No
Exceptional circumstances
No

Therapeutic areas

  • Colitis, Ulcerative
European medicines record
www.ema.europa.eu

First in class
No
Orphan designation
No
Availability
Prescription only

Pharmacology name
mirikizumab
Type
Antibody
Drug name stem
-mab; -mab
Approval recorded by Guide to Pharmacology
Yes

Administration routes

  • Parenteral

  • Action
    Binding
    Action type
    Binding
    Target
    IL-23A
    Gene symbol
    IL-23A
    Median affinity
    10.68
    Affinity units
    pKd
    Primary target
    Yes
  • Mechanism
    Interleukin-23 inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-23
    Protein identifier
    P29460
  • Mechanism
    Interleukin-23 inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-23
    Protein identifier
    Q9NPF7

Open Targets mechanisms

  • Mechanism
    Interleukin-23 inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-23

  • Condition
    Crohn Disease
    Highest recorded phase
    4
    Condition identifier
    EFO:0000384
    Subject identifier
    D003424
  • Condition
    Immune System Diseases
    Highest recorded phase
    4
    Condition identifier
    EFO:0000540
    Subject identifier
    D007154
  • Condition
    Psoriasis
    Highest recorded phase
    3
    Condition identifier
    EFO:0000676
    Subject identifier
    D011565
  • Condition
    Colitis, Ulcerative
    Highest recorded phase
    4
    Condition identifier
    EFO:0000729
    Subject identifier
    D003093
  • Condition
    Inflammatory Bowel Diseases
    Highest recorded phase
    3
    Condition identifier
    EFO:0003767
    Subject identifier
    D015212

  • Condition identifier
    EFO_0000384
  • Condition identifier
    EFO_0000540
  • Condition identifier
    EFO_0000676
    Highest recorded phase
    3
  • Condition identifier
    EFO_0000729
  • Condition identifier
    EFO_0003767
    Highest recorded phase
    3
  • Condition identifier
    EFO_1001494
    Highest recorded phase
    3
  • Condition identifier
    HP_0001513
    Highest recorded phase
    3
  • Condition identifier
    HP_0025502
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005011
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005046
    Highest recorded phase
    4
  • Condition identifier
    MONDO_0005083
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005101
    Highest recorded phase
    4

Dose
300 mg
Route
Intravenous
How often
Every 4 weeks

Conditions of use

  • Infuse over at least 30 minutes

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Disulfide bridges location
    Sequence
    22-96$22''-96''$23'-88'$23'''-88'''$142-198$142''-198''$221-221''$224-224''

  • 0002-1442
  • 0002-3116
  • 0002-7575
  • 0002-7717
  • 0002-7722
  • 0002-8011
  • 0002-8870

Related records

Trials (49)

Approved for (3)

In development for (2)

Targets (2)